Search Results for

Clear All Filters

May 11, 2020

Eleanor Eagan

Blog Post

2020 Election/TransitionCampaign Finance

Biden's No Trumpian Real Estate Tycoon, But Still Receives Heavy Real Estate Backing

With real estate tycoon Donald Trump in the White House, the average American is likely more aware than ever of the many ways the federal government helps to subsidize real estate profits. As the average person increasingly struggles to pay rising housing costs with stagnating wages, real estate giants make out like bandits with the help of tax loopholes and direct subsidies. Already a matter of pressing national concern, this stark disparity is only likely to become more salient in the coming months as the pandemic sheds light on the risks of our housing system’s precarity and undermines many people’s fragile grip on housing stability.

May 11, 2020

Joshua Timi Iwayemi

Blog Post

2020 Election/TransitionCampaign Finance

Diplomacy by Donors

On December 18, 2019, the United States House of Representatives impeached President Donald Trump for withholding military aid from Ukraine as a means to pressure Vladimir Zelensky to investigate Democratic presidential candidate, Joe Biden. One of the key figures in this scandal was Gordon Sondland, then ambassador to the European Union. Sondland had limited diplomatic experience before his appointment, but he had the privilege of donating $1 million to President Trump’s inaugural committee.

May 11, 2020

Miranda Litwak

Blog Post

2020 Election/TransitionCampaign FinanceTech

Biden's Ties to Immigration Enforcement Run Through BigTech

As we creep closer to November’s election, Democratic politicians–progressives and moderates alike–have largely fallen in line behind presumptive Democratic nominee Joe Biden. Even so, Biden must earn the vote of many progressive voters who are wary of his pro-corporate leanings. While Biden showed promise by teaming up with Sanders’ campaign on policy, there is still cause for grave concern. Just last week, the public learned that Larry Summers was advising the Biden campaign. Last month Biden’s donors put out a list of ideal candidates for senior-level administration positions, which included Wall Street big wigs such as BlackRock CEO Laurence Fink, Blackstone executive Tony James, and investment banker Mark Gallogly. Biden’s wealthy donors must be monitored in order to prevent corporate interests from capturing his transition-planning effort.

May 11, 2020

Eleanor Eagan

Blog Post

2020 Election/Transition

Presidential Power Map Provides Road Map to Potential 2020 Transition

The Revolving Door Project’s “Presidential Power Map” provides an easy-to-understand snapshot of 2020 Democratic presidential primary candidates’ support by sector. By breaking down high-dollar support in this way, this tool encourages users to draw direct lines between big money fundraising and a president’s choices regarding personnel and executive power. Using the “Presidential Power Map,” members of the Revolving Door Project’s team have begun to tease out these connections and to consider what they might mean for the composition and priorities of a future administration.

May 11, 2020

Mariama Eversley

Blog Post

2020 Election/TransitionPrivate Equity

Will Biden Rein in Private Equity’s Hold on Healthcare?

Private equity firms play an increasingly central role in financing the healthcare industry. These firm’s investments in healthcare include everything from hospitals to ambulance transport companies to specialized medical services. The industry’s encroachment into healthcare is increasing costs, especially in circumstances where patients have few choices and are in need of immediate medical attention.

May 11, 2020

Mariama Eversley

Blog Post

2020 Election/TransitionPrivate Equity

Private Equity is Making COVID-19 in Nursing Homes Even Worse. A President Biden Could do Something About it.

Private equity (PE) owned nursing homes have a bad reputation. The industry’s, by now infamous, cost-cutting strategies have been shown to lead to measurable declines in patients’ health, safety, and wellbeing when undertaken in the nursing home context. The Carlyle Group’s acquisition of HCR ManorCare in 2011, for example, left patients with “overdoses, bedsores, [and] broken bones” before driving the company into financial ruin.

March 06, 2020 | Talking Points Memo

Eleanor Eagan

Op-Ed

2020 Election/TransitionCongressional Oversight

Congressional Democrats Exhibit Symptoms Of A Spinelessness Pandemic

Public health officials agree: coronavirus’ spread is no longer a matter of if but when. The only question now is, how bad is it going to get? The answer will rest on the efficacy of the government’s response, its ability to get resources where they need to be, keep the public informed and react quickly to new developments. The bad news? We have a president whose team is uniquely ill-suited to lead this process. The good news, however, is the government is larger than the executive.

February 27, 2020 | The American Prospect

Andrea Beaty Eleanor Eagan Max Moran

Op-Ed

2020 Election/TransitionRevolving Door

The Trump Administration’s Contemptuous, Pro-Corporate Response to Coronavirus

The COVID-19 coronavirus is nearly a global pandemic. The Centers for Disease Control’s latest statement warns Americans “to prepare, in the expectation that this could be bad.” Amid a global crisis like this, the public needs true leadership from the president and his top aides, and a highly competent government deserving of the people’s trust, with the capacity to effectively respond to incoming threats.But this is the Trump administration. So instead, we are being asked to put our faith in inexperienced political cronies, servicing the needs of corporations rather than the public, and contemptuous of science, scientists, and the idea of expertise.

February 27, 2020

Andrea Beaty

Blog Post

2020 Election/TransitionCampaign Finance

Biden and Buttigieg See Pharma Money As The Cure For Campaign Woes

HHS secretary Alex Azar refused to guarantee a coronavirus vaccine would be affordable to all during Congressional testimony on Wednesday. The outrage reminded Americans why they are sick and tired of the unchecked pharmaceutical industry’s abuses. As we wrote for the American Prospect, Azar is a former pharma lobbyist who, like the rest of President Trump’s coronavirus response team, has no background in public health or research.